JP2018534263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534263A5 JP2018534263A5 JP2018516487A JP2018516487A JP2018534263A5 JP 2018534263 A5 JP2018534263 A5 JP 2018534263A5 JP 2018516487 A JP2018516487 A JP 2018516487A JP 2018516487 A JP2018516487 A JP 2018516487A JP 2018534263 A5 JP2018534263 A5 JP 2018534263A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- group
- composition
- inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236345P | 2015-10-02 | 2015-10-02 | |
| US201562236729P | 2015-10-02 | 2015-10-02 | |
| US201562236741P | 2015-10-02 | 2015-10-02 | |
| US201562236409P | 2015-10-02 | 2015-10-02 | |
| US62/236,729 | 2015-10-02 | ||
| US62/236,345 | 2015-10-02 | ||
| US62/236,741 | 2015-10-02 | ||
| US62/236,409 | 2015-10-02 | ||
| PCT/US2016/054780 WO2017059252A1 (en) | 2015-10-02 | 2016-09-30 | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187956A Division JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534263A JP2018534263A (ja) | 2018-11-22 |
| JP2018534263A5 true JP2018534263A5 (2) | 2019-11-07 |
Family
ID=57184801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516487A Withdrawn JP2018534263A (ja) | 2015-10-02 | 2016-09-30 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
| JP2020187956A Pending JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187956A Pending JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3355871A1 (2) |
| JP (2) | JP2018534263A (2) |
| AU (1) | AU2016329075A1 (2) |
| CA (1) | CA3000746A1 (2) |
| HK (1) | HK1258762A1 (2) |
| TW (1) | TW201726130A (2) |
| WO (1) | WO2017059252A1 (2) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| CA3116731A1 (en) * | 2018-10-19 | 2020-04-23 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| CN109912584B (zh) * | 2019-03-22 | 2021-08-13 | 中国药科大学 | 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用 |
| CN110403944A (zh) * | 2019-08-07 | 2019-11-05 | 中南大学湘雅医院 | Decernotinib在制备治疗银屑病的外用药物中的应用、药物及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199997B2 (en) * | 2011-11-29 | 2015-12-01 | Ono Pharmaceutical Co., Ltd. | Purinone derivative hydrochloride |
| UY34573A (es) * | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| HK1204926A1 (en) * | 2012-02-29 | 2015-12-11 | 吉联亚生物科技有限公司 | Antibodies to matrix metalloproteinase 9 |
| JP6280546B2 (ja) * | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| JP6478989B2 (ja) * | 2013-11-07 | 2019-03-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法 |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2015146159A1 (en) * | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
| US9949971B2 (en) * | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
-
2016
- 2016-09-30 HK HK19101080.8A patent/HK1258762A1/zh unknown
- 2016-09-30 EP EP16785022.1A patent/EP3355871A1/en not_active Withdrawn
- 2016-09-30 JP JP2018516487A patent/JP2018534263A/ja not_active Withdrawn
- 2016-09-30 AU AU2016329075A patent/AU2016329075A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/054780 patent/WO2017059252A1/en not_active Ceased
- 2016-09-30 CA CA3000746A patent/CA3000746A1/en not_active Abandoned
- 2016-09-30 TW TW105131809A patent/TW201726130A/zh unknown
-
2020
- 2020-11-11 JP JP2020187956A patent/JP2021014466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534263A5 (2) | ||
| TWI794171B (zh) | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 | |
| TWI808055B (zh) | Hdac 抑制劑與 pd-1 抑制劑之組合治療 | |
| JP7307744B2 (ja) | がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体 | |
| JP7592689B2 (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| JP2021523159A5 (2) | ||
| AU2017362040B2 (en) | Dose and regimen for HDM2-p53 interaction inhibitors | |
| CN114209841A (zh) | 治疗组合物、组合和使用方法 | |
| JP2014533284A5 (2) | ||
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2018517686A5 (2) | ||
| US20150266967A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| US11077093B2 (en) | Combination drug | |
| JP5948525B1 (ja) | 癌のための併用療法 | |
| KR102936318B1 (ko) | 소세포폐암의 병용 치료용 퀴놀린 유도체 | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| CN113286614A (zh) | 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合 | |
| CA3105947A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies | |
| TWI812820B (zh) | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 | |
| US20260041693A1 (en) | Combination therapy of cdk7 inhibitors with other anti-cancer therapies | |
| CN113766917A (zh) | 用于治疗头颈癌的喹啉衍生物 | |
| US20230218618A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies | |
| JP2024502465A5 (2) | ||
| WO2021069632A1 (en) | Use of an anti-ccr7 antibody in combination therapies with a btk inhibitor and/or bcl2- inhibitor for treating hematological malignancies | |
| HK40120537A (zh) | 抗肿瘤组合物 |